John McLaughlin developed the idea of The Audit Exchange with the realization that internal auditing and other related business advisory work requires a significant amount of collaboration with management to ensure meaningful and lasting outcomes. Over the past 25 years, he recognized that too often, internal auditing is unnecessarily disruptive to business processes owners, management and the Board, when executed by inexperienced individuals with an insufficient business perspective. The Audit Exchange was created to ensure the most meaningful exchange of experience and perspective between management, the Board and ourselves as business advisors.
Biotechnology company SciGen was established in Singapore in 1988 and has been listed on the Australian Stock Exchange (ASX code SIE) since 2002. SciGen sells recombinant human insulin under the trade name SciLin in Southeast Asia, Australia and Oceania (excluding Japan) under licence from Savient Pharmaceuticals Inc. (formerly known as Bio-Technology General Corp.). The company manufactures and sells licensed biotechnological products, including a recombinant human growth hormone under the trade name SciTropin and a hepatitis B vaccine under the trade name Sci-B-Vac.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA ® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University (" Duke ") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted . and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns . and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the . For more information, please visit the Company's website at .